Publisher
Springer Science and Business Media LLC
Reference19 articles.
1. Eugen K, Holly WS, Elizabeth S, Gopi S. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J Immunol Methods. 2008;333:1–9.
2. Swanson SJ. Immunogenicity issues in drug development. J Immunotoxicol. 2006;3:165–72.
3. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002;346:469–75.
4. Vultaggio A, Maggi E, Matucci A. Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management. Curr Opin Allergy Clin Immunol. 2011;11:262–8.
5. Food and Drug administration. DRAFT. Guidance for industry assay development for immunogenicity testing of therapeutic proteins. U.S. Department of Health and Human Services; 2009.
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献